Dulaglutide (Trulicity) studies: 418 papers with results
Page 8 of 9
- Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Martín V · Advances in therapy · 2020
Not a test of Dulaglutide (Trulicity) alone · 17 results
- A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
Tham LS · Diabetes, obesity & metabolism · 2022
Not a test of Dulaglutide (Trulicity) alone · 9 results
- Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.
Hu S · Diabetes, obesity & metabolism · 2023
Not a test of Dulaglutide (Trulicity) alone · 10 results
- The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.
Inagaki N · Diabetes, obesity & metabolism · 2016
Not a test of Dulaglutide (Trulicity) alone · 5 results
- Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.
Mimura H · Journal of diabetes investigation · 2025
Not a test of Dulaglutide (Trulicity) alone · 13 results
- Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.
Korakas E · Journal of clinical medicine · 2024
Not a test of Dulaglutide (Trulicity) alone · 5 results
- Euglycaemic Ketoacidosis Due to Extremely Low-Calorie Intake and Dehydration After Laparoscopic Sleeve Gastrectomy in a Patient with Type 2 Diabetes.
Liu Z · Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
Not a test of Dulaglutide (Trulicity) alone · 5 results
- Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.
Iwamoto N · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018
Not a test of Dulaglutide (Trulicity) alone · 10 results
- Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications.
Rahman E · Toxicon : official journal of the International Society on Toxinology · 2026
Not a test of Dulaglutide (Trulicity) alone · 20 results
- Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
Ponzo V · Nutrients · 2025
Not a test of Dulaglutide (Trulicity) alone · 10 results
- Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J · BMC medicine · 2024
Not a test of Dulaglutide (Trulicity) alone · 12 results
- Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.
Matza LS · Current medical research and opinion · 2018
Not a test of Dulaglutide (Trulicity) alone · 8 results
- Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
Pantalone KM · Diabetes, obesity & metabolism · 2018
Not a test of Dulaglutide (Trulicity) alone · 4 results
- Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.
Dhanapalaratnam R · Journal of neurophysiology · 2025
Not a test of Dulaglutide (Trulicity) alone · 8 results
- Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
Almeida OP · Diabetes, obesity & metabolism · 2024
Not a test of Dulaglutide (Trulicity) alone · 8 results
- The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.
Basson M · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018
Not a test of Dulaglutide (Trulicity) alone · 7 results
- Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.
Hu S · Frontiers in pharmacology · 2022
Not a test of Dulaglutide (Trulicity) alone · 13 results
- Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.
Lv L · Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025
Not a test of Dulaglutide (Trulicity) alone · 12 results
- Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.
Abdelmannan D · Diabetes research and clinical practice · 2024
Not a test of Dulaglutide (Trulicity) alone · 8 results
- Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.
Barrett A · Advances in therapy · 2023
Not a test of Dulaglutide (Trulicity) alone · 10 results
- Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
Dardano A · Frontiers in endocrinology · 2022
Not a test of Dulaglutide (Trulicity) alone · 4 results
- A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.
Amirthalingam P · Current drug safety · 2026
Not a test of Dulaglutide (Trulicity) alone · 18 results
- Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.
Nigam A · The Journal of the Association of Physicians of India · 2024
Not a test of Dulaglutide (Trulicity) alone · 4 results
- Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist.
Kim AR · Nutrients · 2026
Not a test of Dulaglutide (Trulicity) alone · 4 results
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.
Ali Akbar U · The American journal of cardiology · 2026
Not a test of Dulaglutide (Trulicity) alone · 12 results
- Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study.
Hsu HY · Diabetes research and clinical practice · 2026
Not a test of Dulaglutide (Trulicity) alone · 9 results
- Hepatic portal venous gas in a patient with diabetes on GLP-1 receptor agonist and alpha-glucosidase inhibitor.
Noguchi T · JCEM case reports · 2026
Not a test of Dulaglutide (Trulicity) alone · 4 results
- Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.
Lipska KJ · Annals of internal medicine · 2026
Not a test of Dulaglutide (Trulicity) alone · 16 results
- Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.
Dhali A · Journal of personalized medicine · 2026
Not a test of Dulaglutide (Trulicity) alone · 12 results
- Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes.
Kim MJ · Diabetes research and clinical practice · 2025
Not a test of Dulaglutide (Trulicity) alone · 4 results
- Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists.
Barrett TS · JAMA surgery · 2025
Not a test of Dulaglutide (Trulicity) alone · 9 results
- Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.
Guo H · Frontiers in pharmacology · 2024
Not a test of Dulaglutide (Trulicity) alone · 12 results
- The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2.
Dilla T · Journal of medical economics · 2017
Not a test of Dulaglutide (Trulicity) alone · 6 results
- Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system.
Huang H · British journal of anaesthesia · 2025
Not a test of Dulaglutide (Trulicity) alone · 10 results
- Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.
Noda K · Diabetology international · 2022
Not a test of Dulaglutide (Trulicity) alone · 6 results
- Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
McCrimmon RJ · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
Not a test of Dulaglutide (Trulicity) alone · 9 results
- A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
Pollock RF · Journal of comparative effectiveness research · 2019
Not a test of Dulaglutide (Trulicity) alone · 3 results
- Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
Franek E · Diabetes, obesity & metabolism · 2022
Not a test of Dulaglutide (Trulicity) alone · 3 results
- Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial.
Lee EY · Diabetes research and clinical practice · 2023
Not a test of Dulaglutide (Trulicity) alone · 3 results
- Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP-1 Agonists: Results of a Bicentric Pilot Study.
Romain B · World journal of surgery · 2025
Not a test of Dulaglutide (Trulicity) alone · 10 results
- Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran.
Ekhlasi M · Value in health regional issues · 2022
Not a test of Dulaglutide (Trulicity) alone · 6 results
- Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.
McKone DB · Diabetes spectrum : a publication of the American Diabetes Association · 2025
Not a test of Dulaglutide (Trulicity) alone · 14 results
- Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.
Nakhleh A · Journal of clinical medicine · 2025
Not a test of Dulaglutide (Trulicity) alone · 7 results
- Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.
Park MJ · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
Not a test of Dulaglutide (Trulicity) alone · 12 results
- Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis.
Chen Q · PloS one · 2026
Not a test of Dulaglutide (Trulicity) alone · 9 results
- Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.
Alfonso Arvez MJ · Clinical pharmacology and therapeutics · 2026
Not a test of Dulaglutide (Trulicity) alone · 6 results
- Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study.
Ito K · Diabetology international · 2023
Not a test of Dulaglutide (Trulicity) alone · 3 results
- Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
Lingvay I · BMJ open diabetes research & care · 2020
Not a test of Dulaglutide (Trulicity) alone · 7 results
- Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB · Journal of medical economics · 2020
Not a test of Dulaglutide (Trulicity) alone · 8 results
- Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Ericsson Å · Journal of medical economics · 2019
Not a test of Dulaglutide (Trulicity) alone · 7 results